Department of Biomedicine, CNR Institute of Translational Pharmacology , Rome and L'Aquila, Italy.
Department of Experimental Medicine and Surgery, The University of Rome , Tor Vergata, Italy.
Immunol Invest. 2020 Jul;49(5):489-497. doi: 10.1080/08820139.2020.1737539. Epub 2020 Mar 18.
The relationship between HLA-DRB1 allele polymorphism and breast cancer (BC) development is still unclear and needs further investigation. To address this issue, we analyzed HLA-DRB1 allele frequency (AF) by sequence-based typing (SBT) in 47 patients from central Italy with BC and 156 sex and age-matched healthy controls. Two hundred ninety-seven individuals from the same region were utilized as historical controls. Pearson's chi-square analysis with Yate's correction or Fisher's Exact test with Bonferroni's correction, as appropriate, were used to compare HLA-DRB1 AF differences in patients and controls. A total of 36 HLA-DRB1 alleles were identified. A detailed study showed that HLA-DRB111:01 and HLA-DRB110:01 alleles are significantly associated with increased BC risk. In particular, HLA-DRB111:01 AF was significantly higher in patients with BC than in healthy females and historical controls, even following Bonferroni's correction (stage I-II BC patients vs historical controls p<0.00; stage III-IV BC patients vs female healthy controls p=0.025 and historical controls p<0.00). The HLA-DRB110:01 allele was also positively associated with BC as evidenced by a significantly higher AF in patients with BC than in healthy controls (BC patients stage I-II vs historical controls corrected p =0.01). These results suggest that both HLA-DRB111:01 and HLA-DRB110:01 AF could represent interesting markers in patients at risk of developing BC.
HLA-DRB1 等位基因多态性与乳腺癌(BC)发展之间的关系尚不清楚,需要进一步研究。为了解决这个问题,我们通过基于序列的分型(SBT)分析了来自意大利中部的 47 名 BC 患者和 156 名性别和年龄匹配的健康对照者的 HLA-DRB1 等位基因频率(AF)。来自同一地区的 297 人被用作历史对照。适当使用 Pearson 卡方检验(带 Yate 校正)或 Fisher 精确检验(带 Bonferroni 校正)来比较患者和对照组的 HLA-DRB1 AF 差异。共鉴定出 36 个 HLA-DRB1 等位基因。详细研究表明,HLA-DRB111:01 和 HLA-DRB110:01 等位基因与增加的 BC 风险显著相关。特别是,HLA-DRB111:01 AF 在 BC 患者中明显高于健康女性和历史对照组,即使在经过 Bonferroni 校正后(I-II 期 BC 患者与历史对照组相比 p<0.00;III-IV 期 BC 患者与健康女性对照组和历史对照组相比 p=0.025 和 p<0.00)。HLA-DRB110:01 等位基因也与 BC 呈正相关,这一点从 BC 患者中 HLA-DRB110:01 AF 明显高于健康对照组这一事实得到证实(I-II 期 BC 患者与历史对照组校正后 p=0.01)。这些结果表明,HLA-DRB111:01 和 HLA-DRB1*10:01 AF 均可能成为具有发生 BC 风险的患者的有趣标志物。